Gloria Virginia López;Germán Adrian Galliussi López;Marcelo Hill;Carlos Escande;Mercedes Segovia;Carlos Batthyány;Williams Arturo Porcal Quinta
发明人:
Carlos Batthyány,Gloria Virginia López,Carlos Escande,Williams Arturo Porcal Quinta,Germán Adrian Galliussi López,Marcelo Hill,Mercedes Segovia
申请号：
US16822657
公开号：
US20200215083A1
申请日:
2020.03.18
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Current therapeutic approach to treating heart allotransplantation rejection focus on immunosuppression protocols that carry harmful side effects after chronic use, which include global immune depression to the patient. The present inventors have discovered alternative and synergistic protocols based on inhibiting NF-κB and NLRP3 inflammasome-dependent IL-1βrelease with nitrated NSAID derivatives.
